Natixis Advisors LLC Purchases Shares of 21,245 Catalent, Inc. (NYSE:CTLT)

Natixis Advisors LLC acquired a new position in Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 21,245 shares of the company’s stock, valued at approximately $1,287,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in CTLT. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent during the 2nd quarter worth $42,000. Sentry Investment Management LLC acquired a new position in Catalent during the third quarter worth $53,000. Longfellow Investment Management Co. LLC raised its holdings in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new stake in shares of Catalent during the 3rd quarter worth about $73,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CTLT. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

CTLT stock opened at $60.76 on Wednesday. The stock has a 50-day moving average price of $59.83 and a two-hundred day moving average price of $58.36. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.50. The stock has a market cap of $11.03 billion, a PE ratio of -26.88, a price-to-earnings-growth ratio of 2.42 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. Equities analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock worth $305,931 over the last ninety days. Insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.